LSD for Suicidality

6 papers and 0 clinical trials exploring lsd as a treatment for suicidality.

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM-120 have reignited clinical development.

Full LSD profile
Indication700,000 deaths annually worldwide.

Suicidality

Suicidality encompasses a spectrum of suicidal thoughts and behaviours, significantly impacting individuals globally. Recent research into psychedelics, particularly ketamine and ayahuasca, shows promise in rapidly alleviating suicidal ideation associated with mental health disorders.

Full Suicidality profile

Academic Research

6 papers
Paywallmeta

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

This systematic review and meta‑analysis of 214 studies (3,504 participants with analysable adverse‑event data) found that high‑dose classic psychedelics were generally well tolerated in clinical/research settings, with serious adverse events occurring mainly in ~4% of participants who had preexisting neuropsychiatric disorders and no reports in contemporary trials of suicide, persistent psychotic disorder or hallucinogen‑persisting perception disorder. Common non‑serious adverse events (headache, anxiety, nausea, fatigue, dizziness) had similar prevalences for psilocybin and LSD, but substantial heterogeneity and limited systematic adverse‑event monitoring across studies highlight the need for improved pharmacovigilance.

Published
Journal
JAMA Psychiatry
Authors
Graziosi, M., Hinkle, J. T., Nayak, S., Yaden, D. B.
Open Accessindividual

LSD use in the United States: Examining user demographics and their evolution from 2015-2019

Analysing NSDUH data from 2015–2019, the authors found a 47% increase in past‑year LSD use (0.59% to 0.87%) without a proportional rise in hallucinogen use disorder. Use was linked to greater access and lower perceived risk plus specific sociodemographic and behavioural correlates (e.g. Asian race, low income, fewer children, history of selling drugs, past‑year suicide attempt in adults) and rose among pregnant, 26–34‑year‑old, married respondents and lifetime methamphetamine users, suggesting growing societal acceptance though LSD remains uncommon and not a major driver of public‑health harm.

Published
Journal
MedRvix
Authors
Anand, A., Barnett, B. S., Dewey, E. N., Weleff, J.

Clinical Trials

0 trials

No clinical trials have been tagged with both LSD and Suicidality yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all LSD papers Search all Suicidality trials Full LSD profile Full Suicidality profile